Antigen News and Research

RSS

Researchers develop a mathematical means of assessing COVID-19 tests' false-negative rate

Even with more than 1.5 million Americans receiving a COVID vaccine each day, officials estimate it will take many more months before enough people are protected from the deadly virus.

22 Feb 2021

FDA issues guidance for medical product developers to address the emergence of SARS-CoV-2 variants

Today, the U.S. Food and Drug Administration issued guidances for medical product developers, specifically covering vaccines, diagnostics and therapeutics products, to address the emergence and potential future emergence of variants of SARS-CoV-2, the virus that causes COVID-19.

22 Feb 2021

An overview of spike protein antigen COVID-19 vaccine candidates

A new paper in the journal Reviews in Medical Virology provides a perspective on current vaccine development strategies and tools, which may allow the production of safe and effective vaccines.

22 Feb 2021

Could an intranasal adjuvant to vaccines boost immunity against SARS-CoV-2 variants?

A research team from the University of Michigan Medical School, USA, developed a supplementary intranasal treatment to improve COVID-19 vaccine response and its effects on long-lasting immunity from other variants, such as the B.1.351 variant first found in South Africa.

22 Feb 2021

SARS-CoV-2 DNA vaccine tested in animal model

A team of experts has tested the immune responses elicited by mucosal homologous plasmid and a heterologous immunization strategy using a plasmid vaccine and a Modified Vaccinia Ankara (MVA) expressing SARS-CoV-2 spike (S) and nucleocapsid (N) antigens.

21 Feb 2021

Live attenuated SARS-CoV-2 vaccine candidate shows protective efficacy in vivo

A new preprint on the bioRxiv* server describes the development of a live attenuated vaccine candidate to counter the growing threat of the COVID-19 pandemic.

19 Feb 2021

Llama-derived nanobodies show neutralizing activity against SARS-CoV-2 variants of concern in vitro

A new study reports the development of nanoantibodies (nAbs) – also called or nanobodiesTM or single-domain antibodies – that effectively bind the SARS-CoV-2 spike protein from the ancestral Wuhan variant as well as the recently detected UK and South African variants.

19 Feb 2021

Chicken-derived antibody shows potent neutralizing capacity against SARS-CoV-2 in vitro

Researchers report on a Chicken-derived antibody against SARS-CoV-2, offering preliminary data on a potential therapeutic for COVID-19 warranting further research.

19 Feb 2021

Juvenile inflammatory rheumatic disease associated with higher antibody responses to seasonal coronaviruses

A new study released on the bioRxiv* server compared the antibodies produced in young patients with these three conditions against the two immunodominant coronavirus antigens, the spike and the nucleocapsid antigens.

19 Feb 2021

Understanding the dynamics of brain blood flow could hold key for treating neurologic conditions

While the human brain has over 400 miles of total vasculature, little is known about the tiny capillaries that make up much of this intricate labyrinth of blood vessels critical for delivering oxygenated blood and nutrients to billions of brain cells.

19 Feb 2021

Immune response to SARS-CoV-2 may be limited by a set of genes

Neutralizing antibodies develop within two weeks of a SARS-CoV-2 infection, but their durability and intensity can vary by individual, prompting concerns about the prospects of long-lasting immunity and efficacy of COVID-19 vaccines.

18 Feb 2021

Could measles virus vectors be used for a new COVID-19 vaccine?

A research team at the Institut Pasteur in France describes the successful development of such a vaccine utilizing a measles virus vector.

18 Feb 2021

Clinical trial shows five-year outcomes of CAR T-cell therapy for non-Hodgkin lymphomas

A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the chimeric antigen receptor (CAR) T cell therapy Kymriah, researchers in Penn's Abramson Cancer Center reported today in the New England Journal of Medicine.

18 Feb 2021

SARS-CoV-2 D614G mutation associated with lower antibody binding

The onset of the COVID-19 pandemic has brought about an international effort to uncover the biology of its causative agent, SARS-CoV-2, and to develop effective and safe antivirals to contain and treat the infection. A new study by a team of researchers in France and Sweden discusses one such study, exploring the relative immunogenicity of the three main structural proteins of the virus.

18 Feb 2021

New insights on structural biology may help design more efficient antibodies

In structural biology, some molecules are so unusual they can only be captured with a unique set of tools.

18 Feb 2021

Advancements in DNA vaccines against COVID-19

The rapid spread of the pathogen and the increasing number of cases highlight the need for an effective and safe vaccine. As vaccination efforts roll out in many countries, new types of vaccines, like deoxyribonucleic acid (DNA) vaccines, are under research..

17 Feb 2021

Study reveals role of platelets in the development of lupus

Platelets may play a key role in the development of lupus, according to a study published today by researchers at Université Laval and CHU de Québec-Université Laval Research Center.

17 Feb 2021

Novel hydrogel slowly releases RNA nanovaccines to shrink tumors

Messenger RNA (mRNA) vaccines to prevent COVID-19 have made headlines around the world recently, but scientists have also been working on mRNA vaccines to treat or prevent other diseases, including some forms of cancer.

17 Feb 2021

New model predicts which patients will gain most from PSMA PET scan

A new study led by researchers at the UCLA Jonsson Comprehensive Cancer Center helps identify which patients with prostate cancer will benefit most from the use of prostate-specific membrane antigen PET imaging, PSMA PET, a novel imaging technique that recently was approved by the U.S. Food and Drug Administration.

16 Feb 2021

British and South African SARS-CoV-2 variants show some resistance to neutralizing antibodies

Researchers in France report impaired neutralization of two new SARS-CoV-2 variants by antibodies induced by vaccination or natural infection.

16 Feb 2021

Antigen News and Research

Researchers develop a mathematical means of assessing COVID-19 tests' false-negative rate

FDA issues guidance for medical product developers to address the emergence of SARS-CoV-2 variants

An overview of spike protein antigen COVID-19 vaccine candidates

Could an intranasal adjuvant to vaccines boost immunity against SARS-CoV-2 variants?

SARS-CoV-2 DNA vaccine tested in animal model

Live attenuated SARS-CoV-2 vaccine candidate shows protective efficacy in vivo

Llama-derived nanobodies show neutralizing activity against SARS-CoV-2 variants of concern in vitro

Chicken-derived antibody shows potent neutralizing capacity against SARS-CoV-2 in vitro

Juvenile inflammatory rheumatic disease associated with higher antibody responses to seasonal coronaviruses

Understanding the dynamics of brain blood flow could hold key for treating neurologic conditions

Immune response to SARS-CoV-2 may be limited by a set of genes

Could measles virus vectors be used for a new COVID-19 vaccine?

Clinical trial shows five-year outcomes of CAR T-cell therapy for non-Hodgkin lymphomas

SARS-CoV-2 D614G mutation associated with lower antibody binding

New insights on structural biology may help design more efficient antibodies

Advancements in DNA vaccines against COVID-19

Study reveals role of platelets in the development of lupus

Novel hydrogel slowly releases RNA nanovaccines to shrink tumors

New model predicts which patients will gain most from PSMA PET scan

British and South African SARS-CoV-2 variants show some resistance to neutralizing antibodies

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics